Related Experiment Videos
[Sentinel lymph node identification with methylene blue in cervical cancer]
Song-Hua Yuan1, Li-Zhi Liang, Ji-Hong Liu
1Department of Gynecologic Oncology, Cancer Center, Sun Yat-sen University, Guangzhou, Guangdong, 510060, PR China.
AI Zheng = Aizheng = Chinese Journal of Cancer
|September 15, 2004
Summary
A higher dose of methylene blue (3-4 ml) improves sentinel lymph node (SLN) identification in cervical cancer. This method is crucial for staging and treatment planning in cervical cancer patients.
Area of Science:
- Gynecologic Oncology
- Surgical Pathology
- Medical Imaging
Context:
- Sentinel lymph node (SLN) biopsy is a critical staging procedure in cervical cancer.
- Accurate SLN identification is essential for determining treatment strategies and patient prognosis.
- Methylene blue is a commonly used dye for SLN identification, but optimal usage parameters require further investigation.
Purpose:
- To investigate the influential factors affecting sentinel lymph node (SLN) identification using methylene blue in cervical cancer patients.
- To assess the impact of methylene blue dosage and patient factors (preoperative therapy) on SLN detection rates and false negative rates.
Summary:
- This study evaluated methylene blue for SLN identification in 41 cervical cancer patients.
- The overall SLN detection rate was 75.6%, with higher rates observed using 3-4 ml of methylene blue (100%) compared to 2-3 ml (63%).
- Preoperative radiotherapy/chemotherapy reduced SLN detection rates (61.1% vs. 87.0% without therapy).
Impact:
- The findings suggest an optimal methylene blue dosage of 3-4 ml for improved SLN detection in cervical cancer.
- Accurate SLN identification impacts treatment decisions and patient outcomes.
- Further research may refine SLN mapping techniques in cervical cancer.